04:07 PM EST - Valeant Pharmaceuticals International, Inc. : announced that Afexa Life Sciences Inc.’s Board of Directors confirmed its previous recommendation that Afexa shareholders accept the offer by 1625907 Alberta Ltd. ("Acquireco"), a subsidiary of Valeant, pursuant to which Acquireco has agreed to acquire all of the outstanding common shares of Afexa for $0.71 per share in cash. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading down $1.48 at $40.69.
